Literature DB >> 16731537

Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.

D Errante, D Bernardi, A Bianco, S De Nardi, L Salvagno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16731537     DOI： 10.1093/annonc/mdl113

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell Lymphoma.

Authors:  Stefanie Porkert; Pamela Mai; Constanze Jonak; Felix Weihsengruber; Klemens Rappersberger; Wolfgang Bauer; Ingrid Simonitsch-Klupp; Markus Raderer; Julia Valencak
Journal:  Acta Derm Venereol       Date:  2021-02-02       Impact factor: 3.875

Review 2.  Cutaneous primary B-cell lymphomas: from diagnosis to treatment.

Authors:  Margarida Lima
Journal:  An Bras Dermatol       Date:  2015 Sep-Oct       Impact factor: 1.896

3.  Transient wheal attack corresponding to the tumor lesions of primary cutaneous diffuse large B cell lymphoma, leg type after successive rituximab treatment.

Authors:  Saori Itoi; Atsushi Tanemura; Misa Hayashi; Naoko Nagata; Mamori Tani; Ichiro Katayama
Journal:  Case Rep Dermatol       Date:  2014-09-11

4.  Epidermolysis bullosa acquisita as an adverse effect from rituximab therapy: A case report.

Authors:  Xueqiong Wu; Zhenhui Lv; Wenjia Li; Zhaosheng Meng; Shaw P Wan
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.